Venatorx Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of VNRX-9945
MALVERN, PA — Venatorx Pharmaceuticals this week announced that the first patient was dosed in a Phase 1 clinical trial evaluating VNRX-9945, a highly potent, broadly active viral replication inhibitor …
Venatorx Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of VNRX-9945 Read More